[1] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol.2019.70:151-171.
[2] Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol.2011.6:425-56.
[3] Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol.2003.38:257-265.
[4] Chu AL, Schilling JD, King KR, et al. The Power of Single-Cell Analysis for the Study of Liver Pathobiology. Hepatology,2021,73:437-448.
[5] Ramachandran P, Dobie R, Wilson-Kanamori JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature,2019,575:512-518.
[6] Loft A, Alfaro AJ, Schmidt SF, et al. Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication. Cell Metab,2021,33:1685-1700.e9.
[7] Michels BE, Mosa MH, Streibl BI, et al. Pooled In?Vitro and In?Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids. Cell Stem Cell, 2020,26:782-792.e7.
[8] Turner RJ, Golz S, Wollnik C, et al. A Whole Genome-Wide Arrayed CRISPR Screen in Primary Organ Fibroblasts to Identify Regulators of Kidney Fibrosis. SLAS Discov,2020,25:591-604.
[9] Dara S, Dhamercherla S, Jadav SS, et al. Machine Learning in Drug Discovery: A Review. Artif Intell Rev,2022,55:1947-1999.
[10] Wooden B, Goossens N, Hoshida Y, et al. Using Big Data to Discover Diagnostics and Therapeutics for?Gastrointestinal and Liver Diseases. Gastroenterology, 2017,152:53-67.e3.
[11] Thabut D, Routray C, Lomberk G, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology,2011,54:573-585.
[12] Bruschi FV, Claudel T, Tardelli M, et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology,2017,65:1875-1890.
[13] He NY, Li Q, Wu CY, et al. Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives. Acta Pharmacol Sin,2017,38:301-311.
[14] Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol,2008,26:431-442.
[15] Wong L, Yamasaki G, Johnson RJ, et al. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest,1994,94:1563-1569.
[16] Vallverdú J, Martínez García de la Torre RA, Mannaerts I, et al. Directed differentiation of human induced pluripotent stem cells to hepatic stellate cells. Nat Protoc,2021,16:2542-2563.
[17] Ouchi R, Togo S, Kimura M, et al. Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids. Cell Metab,2019,30:374-384.e6.
[18] Paish HL, Reed LH, Brown H, et al. A Bioreactor Technology for Modeling Fibrosis in Human and Rodent Precision-Cut Liver Slices. Hepatology,2019,70:1377-1391.
[19] Bhatia SN, Underhill GH, Zaret KS, et al. Cell and tissue engineering for liver disease. Sci Transl Med,2014,6:245sr2.
[20] Proctor WR, Foster AJ, Vogt J, et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol, 2017,91:2849-2863.
[21] Alonso C, Fernández-Ramos D, Varela-Rey M, et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology, 2017,152:1449-1461.e7. |
